CClinicalTrials.gg
Active, not recruitingNCT07145684OSanDiaBéUpdated May 15, 2026

Culturally Tailored Nutrition Therapy to Improve Dietary Adherence of Type 2 Diabetes Patients in Benin, Africa

An interventional study of A culturally tailored medical nutrition therapy in Type 2 Diabetes, sponsored by University of Arizona. Active, not recruiting at 1 site in Benin. Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by University of Arizona · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

The clinical trial aims to assess the effectiveness of the Objectif Santé Diabète Benin (OSanDiaBé), a culturally tailored medical nutrition therapy (MNT), in enhancing diabetes management and nutrition choices. The investigators hypothesize that participants receiving OSanDiaBé will demonstrate greater improvements in dietary adherence and greater reductions in HbA1c at 6 months compared with those receiving usual care. The investigators further hypothesize that these improvements will be maintained at 12 months following the end of active intervention contact.

Read the detailed description

This study is a 12-month, parallel-group, randomized controlled trial involving individuals diagnosed with type 2 diabetes. Participants will be randomly assigned in a 1:1 ratio to either (1) usual care (wait-list control group) or (2) nutrition counseling with group-based education (intervention group). The intervention group will receive the OSanDiaBé resource package, which includes a workbook, and an Eating Plan based on the 4-A framework of food security. They will participate in four individual home sessions and eight group sessions in the first six months, with no contact between months six and twelve. The primary outcome will be the change in HbA1c levels, while secondary outcomes will include lipid profile, anthropometric measures, dietary adherence, diabetes self-efficacy, and diabetes-related quality of life. All outcomes will be assessed at baseline, 3, 6, and 12 months.

02

Conditions studied

  • Type 2 Diabetes

Keywords

  • Type 2 Diabetes
  • Cultural Adaptation
  • Medical Nutrition Therapy
  • Dietary Adherence
  • Africa
03

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • outpatient in one of the participating health centers
  • be aged between 40 and 65 years old,
  • have a confirmed diagnosis of T2D for a year or longer,
  • with uncontrolled diabetes (HbA1c >7%)
  • able to read and write in French or a support who read and write in French
  • self-identify as Beninese (born in Benin or have parents from Benin),
  • willing to commit to the study and able to attend weekly meetings
  • have family member support for behavioral change
  • suitable for general diet and lifestyle advice (i.e., no complex diet needs; suitability determined by the referring healthcare provider)
  • be willing to provide informed consent to participate.

Exclusion criteria

Exclusion criteria

  • being pregnant, breastfeeding or planning pregnancy,
  • participants with type 1 diabetes
  • use of medication that might affect weight loss
  • planning to travel before the end of the intervention
  • have recent cardiovascular complications (e.g., myocardial infarction, stroke, and congestive heart failure),
  • currently involved in a similar nutritional educational program (to avoid contamination bias).
  • unable to provide consent (e.g., cognitive impairment).
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    OSanDiaBé intervention

    The Objectif Sante Diabète Bénin (OSanDiaBé) intervention group will participate in four individual home sessions and eight group sessions in the first six months, with no contact between months six and twelve. They will receive the OSanDiaBé resource package, which includes a workbook and an Eating Plan based on the 4-A framework of food security.

    Behavioral: A culturally tailored medical nutrition therapy

  • No intervention
    Individual standard care

    The Individual standard care arm will be a wait-list control group who will receive standard care, including blood glucose management and general lifestyle advice, and will access the OSanDiaBe program at the end of the intervention for equitable treatment.

Interventions

  • BehavioralA culturally tailored medical nutrition therapy

    This MNT intervention combines evidence-based menu plans based on the 4A framework of food security with individual nutrition counseling and group diabetes education.

05

What researchers measure

Primary outcomes

  1. Hemoglobin A1C (HbA1C)

    A hemoglobin A1C (HbA1C) test is a blood test that shows the average level of blood glucose over the past two to three months.

    Time frame: HbA1c will be assessed at baseline, 3, 6, and 12 months.

Secondary outcomes

  1. Adherence to dietary recommendations

    Dietary adherence will be assessed using the modified UK Diabetes and Diet Questionnaire (UKDDQ), which consists of 22 items on dietary patterns. Responses indicate food consumption frequency and are coded as follows: A=5 (healthy), B=4 (healthy), C=3 (less healthy), D=2 (less healthy), E=1 (unhealthy), F=0 (unhealthy). Final scores range from 0 to 5, with higher scores indicating better dietary habits.

    Time frame: Dietary adherence will be assessed at baseline, 3, 6, and 12 months.

  2. Weight

    Weight will be measured in kilograms to the nearest 0.1 kg with a standard weighing scale (Hana model, China) while ensuring the participants wear light clothing and no shoes.

    Time frame: Weight will be assessed at baseline, 3, 6, and 12 months.

  3. Height

    Height will be measured with a stadiometer to the nearest 0.1 cm.

    Time frame: Height will be assessed at baseline, 3, 6, and 12 months.

  4. Body mass index

    The BMI (Body Mass Index) will be calculated using the formula: weight (kg) divided by height (m) squared. WHO classifications will be used for adult BMI: underweight (under 18.5 kg/m2), normal weight (18.5 to 24.9), overweight (25 to 29.9), and obese (30 or more).

    Time frame: BMI will be assessed at baseline, 3, 6, and 12 months.

  5. Waist circumference

    The waist circumference will be measured at the umbilicus using a non-elastic tape measure while the participant stood upright, recorded in centimeters.

    Time frame: Waist circumference will be assessed at baseline, 3, 6, and 12 months.

  6. Blood pressure

    The blood pressure will be measured with a sphygmomanometer.

    Time frame: Blood pressure will be assessed at baseline, 3, 6, and 12 months.

  7. Lipid profile

    Lipid profile will include triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).

    Time frame: Lipid profile will be assessed at baseline, 3, 6, and 12 months.

  8. Behavioral outcomes

    The investigators will use the Academy's Evidence-Based Nutrition Practice Guidelines (AEBNPG) for MNT to track behavioral changes in meal planning, food preparation, and physical activity, rating adherence on a scale of 1 (never) to 5 (consistently).

    Time frame: Behavioral outcomes will be assessed at baseline, 3, 6, and 12 months.

06

Study locations

1 site
  • University of Abomey-Calavi
    Cotonou, Littoral Department, Benin
07

References and documents

Individual participant data

Plan to share: Yes — Data obtained from this study may be shared with qualified researchers who have an academic interest in type 2 diabetes. Any data or samples provided will be coded and will not include any personal health information (PHI). Before sharing the data, the request must receive approval, and all necessary agreements (such as a material transfer agreement) must be in place.

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07145684
Lead sponsor
University of Arizona
Collaborators
Fogarty International Center of the National Institute of Health
Responsible party
Halimatou Alaofe (Associate Professor, University of Arizona) — Principal investigator
First posted
Aug 28, 2025
Start date
Sep 8, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
May 15, 2026

Study contacts

Waliou Amoussa-Hounkpatin, PhD
principal investigator · Université d'Abomey-Calavi
Edward Bedric, PhD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion